My son was scheduled for an infusion of Elevidys to possibly prolong the effects of his terminal diagnosis of Duchenne Muscular Dystrophy. The FDA has recently halted all shipments of this pivotal drug due to 'safety' concerns. Without this drug, families like mine are left with zero viable treatment options, perpetuating a cycle of despair and helplessness in the face of a cruel disease.

Duchenne Muscular Dystrophy is a devastating condition with limited avenues for treatment. Elevidys has been seen as a beacon of hope in the marathon against time and disease progression. For families who have already witnessed the slow and inevitable deterioration of their loved ones, Elevidys represents more than just a treatment — it could mean more time, more memories, and more hope.

The sudden and blanket decision by the FDA to stop its shipments strikes a devastating blow to the families who were counting on its timely availability. While safety is paramount, so is the urgent need for innovative treatments that alleviate symptoms and prolong the lives of those with limited options. This doesn't only affect those currently scheduled for treatments but also impacts the wider community, fostering an environment where hope is routinely dashed.

It is crucial that the FDA reconsiders its decision and works collaboratively with Sarepta to address these 'safety' concerns without derailing existing and potential treatments. We urge them to prioritize finding a resolution for the benefit of the thousands affected by this disease, ensuring that decisions are balanced with both safety and patient access in mind.

Sign this petition to push the FDA to reconsider its stance and work towards a solution that doesn’t compromise the treatment potential for those in dire need.